Still Sick After Antibiotics: Tracking Post-Treatment Lyme Symptoms

Your last antibiotic dose was six weeks ago. Your doctor says you're treated, but the fatigue, the brain fog, and the joint pain have not moved.

You're not imagining it. And you're not the only one.

The honest explanation

Post-treatment Lyme disease syndrome, or PTLDS, is what clinicians call the cluster of symptoms that persist after a standard antibiotic course. The CDC's working definition requires symptoms that cause a meaningful reduction in daily activities and last six months or more after treatment ends. Estimates put the number at 10 to 20 percent of people treated for Lyme disease, which is tens of thousands of Americans every year.

In 2026, the U.S. Department of Health and Human Services officially acknowledged, for the first time, that a substantial subset of Lyme patients experiences persistent, often disabling symptoms despite completing guideline-based treatment. HHS described these as "Lyme infection-associated chronic conditions." That language matters. It marks a shift in how the federal government talks about something that has, for years, been a contested subject.

What drives PTLDS is not yet fully understood. A 2024 review in Frontiers in Microbiology found evidence for several possible mechanisms: immune dysfunction, autoimmune responses, small fiber neuropathy, and residual bacterial material triggering ongoing inflammation. Some patients show detectable changes on brain neuroimaging. Others have neuropathic pain with no structural cause on standard imaging. This is an active area of research, not a closed book.

What all of this means practically: "your antibiotics worked" and "you are still sick" are both true at once for a significant subset of patients. One does not cancel out the other.

What patients report

The symptom pattern in PTLDS is consistent across studies, even when severity differs dramatically from person to person.

Fatigue tops nearly every list. Not ordinary tiredness, but the kind that does not resolve with sleep and worsens after physical or mental effort. This pattern has a name in related conditions: post-exertional malaise. Many PTLDS patients recognize the description immediately.

Cognitive symptoms are the second most common cluster: word-finding difficulties, short-term memory gaps, slow processing, difficulty concentrating for more than a few minutes at a stretch. A 2016 to 2020 Belgian cohort study found that 45 percent of patients reported neurocognitive difficulties at six months post-treatment. That is not a rare edge case.

Joint and muscle pain is the third consistent finding, and it often migrates, meaning it moves between locations from day to day. The migrating quality is one of the things that makes PTLDS symptoms easy for others to dismiss and hard for patients to describe.

Sleep disruption, mood changes, and headaches round out the most common complaints. Several of these overlap directly with acute Lyme, which is part of why it's genuinely hard to tell from memory alone whether you're improving or not. Memory is not reliable enough to detect a slow trend.

What tracking it looks like in practice

A daily log earns its value precisely here. Slow recovery looks like stagnation when you are living inside it. The numbers tell a different story.

Here is a realistic three-month arc from a patient with PTLDS who started tracking at week eight post-antibiotics:

Week 8: Fatigue 4/5, brain fog 4/5, joint pain 3/5. Sleep 5 hours broken. Barely working.

Week 10: Fatigue 4/5, brain fog 3/5, joint pain 3/5. Sleep slightly better, 6 hours.

Week 14: Fatigue 3/5, brain fog 3/5, joint pain 2/5. Working half days.

Week 18: Fatigue 3/5, brain fog 2/5, joint pain 2/5. Sleep 7 hours most nights.

At week 18, she would have told you she felt "about the same as always." The log said otherwise. Brain fog had dropped from 4 to 2. Joint pain had dropped from 3 to 2. Fatigue was moving, just slowly.

That data also showed her which symptoms were recovering faster. Brain fog was tracking ahead of fatigue. Joint pain improved when sleep improved. Those connections do not announce themselves in real time. They show up when you look across weeks of entries.

How LymeTrack handles it

The 5-step daily check-in takes about two minutes. That matters when energy is scarce. You rate each tracked symptom on a 1 to 5 scale, log which treatments or supplements you're using, and record relevant factors: sleep duration, stress, activity level, diet changes, weather. That's the raw material.

Over weeks, the Compass and Insights view graphs those ratings over time. A fatigue score of 3 this week means something different if it was a 4 three weeks ago. Without the context, the number is just a number. In the graph, it's a trend.

The treatment-symptom correlation feature has particular value in PTLDS, because many patients cycle through multiple approaches: rest protocols, anti-inflammatory regimens, additional antibiotics, low-dose naltrexone, herbal protocols, and others. LymeTrack records which treatments were active on which days. The Compass can show you which combinations were present during stretches when your symptom scores were lower. That's not a controlled study. It is a way to notice patterns that otherwise get buried in the ordinary chaos of managing a long illness.

The doctor-shareable report turns months of daily data into something concrete you can hand a clinician. Many PTLDS appointments stall on "how are you feeling lately?" A graph of your weekly average fatigue scores over 90 days gives your doctor a starting point that a verbal summary cannot.

Further reading

Three sources worth keeping open:

• HHS Lyme Disease: Invisible Illness. The federal government's dedicated page covering Lyme disease, persistent symptoms, and the 2026 initiatives including a clinician locator and open-data resources.
• What Makes It Tick: Exploring Mechanisms of PTLDS (PMC, 2024). A peer-reviewed review examining what current research proposes is happening biologically in post-treatment patients.
• Risk Factors for PTLDS: Long Island Cohort Study (PMC, 2025). A prospective cohort study looking at which patient characteristics at diagnosis predict persistent symptoms after treatment.